Combination therapy of dexamethasone, rituximab, and cyclosporine for adults with primary immune thrombocytopenia: a prospective observational study.

IF 2.3 4区医学 Q2 HEMATOLOGY

Expert Review of Hematology Pub Date : 2024-11-01 Epub Date: 2024-10-28 DOI:10.1080/17474086.2024.2420633

Ying Liang, Cong Tang, Chunyu Liu, Lu Zhang, Yongguang Fang, Aixiang Zhao, Nannan Chen

{"title":"Combination therapy of dexamethasone, rituximab, and cyclosporine for adults with primary immune thrombocytopenia: a prospective observational study.","authors":"Ying Liang, Cong Tang, Chunyu Liu, Lu Zhang, Yongguang Fang, Aixiang Zhao, Nannan Chen","doi":"10.1080/17474086.2024.2420633","DOIUrl":null,"url":null,"abstract":"Background: To assess the effectiveness of the combination of dexamethasone, rituximab, and cyclosporine in treating adults with primary immune thrombocytopenia (ITP).Research design and methods: This prospective study enrolled consecutive adult patients diagnosed with ITP at the 967th Hospital of the Chinese People's Liberation Army Joint Service Support Force Hospital between November 2019 and February 2023.Results: Twenty-eight patients (13 males, median age 43.5 years) were included. All patients previously experienced ineffective or relapsed ITP, with a median disease duration of 26.5 (range, 7-72) months. At baseline, the median platelet (PLT) count was 13.5 × 109/L (8.25-20 × 109/L). Following treatment, the PLT counts were significantly increased at weeks 1, 3, and 4. The early response rates at weeks 1 and 4 were 82.1% (23/28 patients) and 71.4% (20/28 patients), respectively. The 1-, 3-, and 6-month response rates were 71.4% (20/28), 67.9% (19/28), and 75% (21/28). The treatment-free survival rates at 12 and 24 months were 82.35% (14/17) and 71.43% (10/14), respectively. Six patients experienced transient adverse reactions.Conclusions: The combination of dexamethasone, rituximab, and cyclosporine may present a promising therapeutic option for patients with refractory ITP, with good tolerability and mild adverse reactions.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"855-860"},"PeriodicalIF":2.3000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2024.2420633","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To assess the effectiveness of the combination of dexamethasone, rituximab, and cyclosporine in treating adults with primary immune thrombocytopenia (ITP).

Research design and methods: This prospective study enrolled consecutive adult patients diagnosed with ITP at the 967th Hospital of the Chinese People's Liberation Army Joint Service Support Force Hospital between November 2019 and February 2023.

Results: Twenty-eight patients (13 males, median age 43.5 years) were included. All patients previously experienced ineffective or relapsed ITP, with a median disease duration of 26.5 (range, 7-72) months. At baseline, the median platelet (PLT) count was 13.5 × 10⁹/L (8.25-20 × 10⁹/L). Following treatment, the PLT counts were significantly increased at weeks 1, 3, and 4. The early response rates at weeks 1 and 4 were 82.1% (23/28 patients) and 71.4% (20/28 patients), respectively. The 1-, 3-, and 6-month response rates were 71.4% (20/28), 67.9% (19/28), and 75% (21/28). The treatment-free survival rates at 12 and 24 months were 82.35% (14/17) and 71.43% (10/14), respectively. Six patients experienced transient adverse reactions.

Conclusions: The combination of dexamethasone, rituximab, and cyclosporine may present a promising therapeutic option for patients with refractory ITP, with good tolerability and mild adverse reactions.

查看原文本刊更多论文

地塞米松、利妥昔单抗和环孢素联合治疗成人原发性免疫性血小板减少症：一项前瞻性观察研究。

研究背景目的：评估地塞米松、利妥昔单抗和环孢素联合治疗成人原发性免疫性血小板减少症（ITP）的疗效：这项前瞻性研究招募了2019年11月至2023年2月期间在中国人民解放军联勤保障部队第967医院确诊为ITP的连续成年患者：共纳入28名患者（13名男性，中位年龄43.5岁）。所有患者都曾经历过无效或复发的 ITP，中位病程为 26.5 个月（7-72 个月）。基线时，血小板（PLT）计数中位数为 13.5 × 109/L（8.25-20 × 109/L）。治疗后，血小板计数在第 1、3 和 4 周显著增加。第 1 周和第 4 周的早期反应率分别为 82.1%（23/28 例患者）和 71.4%（20/28 例患者）。1个月、3个月和6个月的反应率分别为71.4%（20/28）、67.9%（19/28）和75%（21/28）。12个月和24个月的无治疗生存率分别为82.35%（14/17）和71.43%（10/14）。6名患者出现了短暂的不良反应：结论：地塞米松、利妥昔单抗和环孢素联合治疗难治性ITP患者可能是一种很有前景的治疗选择，耐受性好，不良反应轻微。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.